EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study

A-S Viskens, L Bollens, E Borgers, S Halewyck, V Hox, M Jorissen, W Lemmens, F Rogister, K Speleman, L Van Gerven, O Vanderveken, B Verhaeghe und 3 weitere

Rhinology Journal · 2025

DOI: 10.4193/rhin24.509 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Rhinology Journal, 2025. Verfasst von A-S Viskens und 14 weiteren Autor:innen. Beteiligte Einrichtung: KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Unit, Leuven, Belgium;Faculty of Medic…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Polyps, Omalizumab, Rhinitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Double-blinded placebo-controlled trials have revealed the efficacy of mepolizumab and omalizumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). However, real-world efficacy (RWE) data, data on therapeutic response and level of disease control for both biologicals are lacking. Methodology: 167 patients with uncontrolled severe CRSwNP, meeting national reimbursement criteria, were included with follow-up over 24 weeks. Primary outcomes included changes in nasal congestion (NCS), nasal polyp score (NPS), VAS-scores, SNOT-22, ACQ-5, and AQLQ scores. Secondary outcomes were therapeutic response and disease control according to EUFOREA/EPOS criteria.

Results

Of the 167 CRSwNP patients, 144 received mepolizumab and 23 omalizumab. After 24 weeks, Patient reported outcomes and NPS significantly improved for both biologicals, with significant effects seen at 12 weeks, with further reduction in NPS by 24 weeks in mepolizumab patients. 74% of patients on omalizumab and 81% of patients on mepolizumab continued their therapy beyond 24 weeks, with 47% and 45% of patients on omalizumab and mepolizumab respectively showing an excellent therapeutic response, with only one out of seven having no/poor response. Disease control was reached in one third of the patients at 24 weeks.

Conclusions

Both mepolizumab and omalizumab significantly improved patient-reported outcomes after 24-weeks, with major effects already observed at 12 weeks. Follow-up beyond 24-weeks might reveal additional effects on both control and remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNasal PolypsOmalizumabRhinitisSinusitisAdultFemaleHumansMaleMiddle AgedBelgiumChronic DiseasePatient Reported Outcome MeasuresRhinosinusitisSeverity of Illness IndexTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedmepolizumabOmalizumab

Autor:innen und Institutionen

  • KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Unit, Leuven, Belgium;Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Faculty of Medicine, KU Leuven, Leuven, Belgium.
  • Department of Otorhinolaryngology-Head and Neck Surgery, UZ Leuven, Leuven, Belgium.
  • Department of Otorhinolaryngology, University Hospital Brussels, Jette, Belgium.
  • Department of Otorhinolaryngology, University Hospital Saint-Luc, Brussels, Belgium.
  • Department of Otorhinolaryngology-Head and Neck Surgery, UZ Leuven, Leuven, Belgium;Laboratory of Experimental Otorhinolaryngology, Department of Neurosciences, KU Leuven, Leuven, Belgium.

Zitieren

APA

Viskens, A. S., Bollens, L., Borgers, E., Halewyck, S., Hox, V., Jorissen, M., Lemmens, W., Rogister, F., Speleman, K., Van Gerven, L., Vanderveken, O., Verhaeghe, B., Vroegop, A., Martens, K., & Hellings, P. W. (2025). Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study. Rhinology Journal. https://doi.org/10.4193/rhin24.509

Vancouver

Viskens AS, Bollens L, Borgers E, Halewyck S, Hox V, Jorissen M, et al. Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study. Rhinology Journal. 2025. doi:10.4193/rhin24.509

BibTeX
@article{Viskens2025,
  author = {Viskens, A-S and Bollens, L and Borgers, E and Halewyck, S and Hox, V and Jorissen, M and Lemmens, W and Rogister, F and Speleman, K and Van Gerven, L and Vanderveken, O and Verhaeghe, B and Vroegop, A and Martens, K and Hellings, P W},
  title = {Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study},
  journal = {Rhinology Journal},
  year = {2025},
  doi = {10.4193/rhin24.509}
}
Kostenlos starten →